Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 27;104(3):485–496. doi: 10.3324/haematol.2018.197749

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2019 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 5. — NRF2 confers cytarabine (Ara-C) resistance partly through the activation of DUSP1 in myelodysplastic syndrome (MDS). (A) Ara-C and (E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one (BCI) have synergistic effects in NRF2 agonist-treated SKM-1 cells. (B) DUSP1 shRNA-1 sensitized SKM-1 cells to Ara-C treatment. (C) DUSP1 shRNA-1 re-sensitized NRF2 agonist treated SKM-1 cells to Ara-C treatment. (D) DUSP1 shRNA-1 enhanced apoptosis induced by Ara-C in SKM-1 cell lines. (E) DUSP1 shRNA-1 induced S phrase arrest in SKM-1. *P<0.05; **P<0.01; ***P≤0.001.